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The introduction of multidrug schedules incorporat-
ing targeted agents has significantly improved the prog-
nosis of patients with metastatic colorectal cancer, with 
a median overall survival (OS) surpassing three years in 
several clinical trials. This improvement of prognosis in 
the general population unveiled a poor prognosis associ-
ated with the presence of BRAF V600E mutation, with 
a median OS of only 12 months. Based on the success of 
BRAF inhibitors in BRAF V600E mutated melanoma, 
several attempts to utilise those drugs in patients with 
BRAF V600E mutated colorectal cancer were under-
taken, but the activity of monotherapy with anti-BRAF 
agents was disappointing. However, the improvement in 
understanding the molecular effects of V600E mutations 
and mechanisms behind secondary resistance to BRAF 
inhibitors through MEK signalling pathway enabled the 
utilisation of BRAF V600E as a molecular target even 
in patients with metastatic colorectal cancer. The results 
of the BEACON study, which evaluated multiagent 
BRAF V600E inhibition in colorectal cancer, suggest 
a major shift in treatment strategy: introduction of the 
first multidrug schedule without classic cytotoxic drugs 
in colorectal cancer.
The BEACON study, published on 20th September 
2019 in the “New England Journal” of Medicine by Kop-
etz et al. [1], was a randomised, open-label, phase III trial 
that compared the combination of encorafenib (BRAF 
inhibitor) and cetuximab (anti-EGFR antibody) with or 
without addition of binimetinib (MEK inhibitor), with 
a standard second-line chemotherapy: FOLFIRI with 
the addition of cetuximab. The study included patients 
with BRAF V600E mutated colorectal cancer, who failed 
one or two lines of therapy. The trial’s primary endpoint 
was overall survival in patients receiving triplet-therapy 
as compared to standard therapy, with an additional pri-
mary endpoint that compared the response rates (RR). 
Major secondary endpoints included a comparison of OS 
in patients receiving doublet therapy compared to a stan-
dard arm, and a comparison of progression-free survival 
(PFS) between arms. From 1677 screened patients, 
665 patients underwent randomisation in 1:1:1 ratio to 
all arms of the trial. After a median follow-up time of 
7.8 months, the trial met its primary endpoint. Median 
OS in patients receiving encorafenib, binimetinib, and 
cetuximab was 9.0 months (95% confidence interval 
[CI] 8.0–11.4) as compared to only 5.4 months (95% 
CI 4.8–6.6) in patients receiving standard therapy, 
with a hazard ratio (HR) of 0.52 (95% CI 0.39–0.70; 
p < 0.001). The second primary endpoint — RR — was 
also significantly improved in patients receiving triplet 
therapy (26%; 95% CI 18–35) in comparison with the 
control arm (2%; 95% 0–7) (p < 0.001). The achieved 
results were consistent among most analysed sub-
groups, with a reduced benefit from triplet therapy in 
the North America region. Survival was also improved 
in patients receiving encorafenib with cetuximab, with 
a median OS of 8.4 months (95% CI 7.5–11.0) and HR 
of 0.60 (95% CI 0.45–0.79; p < 0.001), when compared 
to the control arm. A comparison of triplet therapy with 
doublet therapy, although not prefigured in the protocol, 
showed a trend for OS improvement with triplet thera-
py (HR 0.79; 95% CI 0.59–1.06). Analysis of PFS also 
demonstrated benefit of both triplet (4.3 months; 95% 
CI 4.1–5.2) and doublet (4.2 months; 95% CI 3.7–5.4) 
therapy versus the standard arm (1.5 months; 95% CI 
1.5–1.7). As expected, the toxicity profile differed signifi-
cantly between study arms, with a moderate increase of 
skin and gastrointestinal toxicities with triplet therapy. 
The rate of grade 3 or higher adverse events was 58% 
in patients receiving triplet therapy, 50% in patients 
receiving doublet therapy, and 61% in patients receiving 
standard chemotherapy. The rate of adverse events that 
led to treatment discontinuation was, respectively, 7%, 
8%, and 11%. Additionally, no difference in the rate of 
adverse events that led to death was seen.
Significant OS benefit achieved in the BEACON 
study with both triplet and doublet targeted therapy 
can be considered as a major breakthrough in the 
treatment of patients with BRAF V600E mutated 
colorectal cancer. This is the first trial dedicated to 
patients with colorectal cancer that showed significant 
clinical benefit associated with combining molecularly 
targeted agents with acceptable toxicity profile. Based 
on these results, a combination of encorafenib with 
cetuximab with the addition of binimetinib should be 
considered the new standard of care in the second-line 
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treatment of patients with BRAF V600E mutated col-
orectal cancer. Nevertheless, attention should be paid 
to the significant patient selection, because the trial 
included fewer than 40% of screened patients, which 
mirrors the exceptionally poor prognosis among this 
group of patients. Traditionally, as is the case of most 
modern targeted therapies or immunotherapeutic 
agents, the single most important factor limiting wide 
implementation of this strategy is the cost of a therapy 
that utilises not just two, but three molecularly targeted 
agents. Cost-effectiveness assessment of triplet therapy 
may lead to disappointing conclusions, especially when 
including the only slightly inferior results achieved with 
doublet therapy.
Nivolumab and ipilimumab as a first-line treatment of patients with non-small cell 
lung cancer
The introduction of immune check-point inhibitors 
(CPSs) is probably the single greatest achievement of 
the last decade in the systemic treatment of solid tu-
mours. We must be aware that modern immunotherapy 
is not a universal solution in all solid tumours, but it has 
significantly revolutionised the treatment of several can-
cer types, including melanoma, renal cell carcinoma, and 
lung cancer. The benefit of CPIs in the treatment of pa-
tients with lung cancer, although numerically lower when 
compared to gains in melanoma or renal cell carcinoma, 
has its greatest impact on modern oncology practice due 
to the higher prevalence of lung cancer. Considering 
the actual guidelines, it seems that all patients with 
non-small cell lung cancer, excluding patients with 
present activating mutations (EGFR/ROS/ALK/BRAF), 
should receive CPIs in the first-line treatment — either 
as a monotherapy (in cases with PD-L1 > 50%) or as 
a combination with chemotherapy (in cases with PD-
-L1 < 50%). The number of phase III trials assessing 
CPIS with initial or complete data, which were published 
within the last two years might be intimidating, and we 
can even assume that the current standard will become 
at least partially obsolete in the near future. The role of 
platinum-based chemotherapy doublets, the long-time 
standard of care in the first-line treatment of non-small 
cell lung cancer, is now limited and may even become 
marginalised. This scenario is becoming a reality with the 
recent publication of a trial assessing the combination 
of nivolumab with ipilimumab in the first-line treatment 
of non-small cell lung cancer, which expands the che-
motherapy-free approach also into the population with 
PD-L1 expression below 50%.
The results of the aforementioned trial were pub-
lished on 28th September 2019 in the “New England 
Journal of Medicine” by Hellmann et al. [2]. The Check-
Mate 227 trial was a randomised, open-label, phase III 
trial that compared nivolumab alone or in combination 
with either ipilimumab or chemotherapy with a standard 
platinum-doublet chemotherapy. Patients recruited into 
the trial had non-small cell lung cancer, either squa-
mous carcinoma or adenocarcinoma, without activating 
mutations in the EGFR gene or the presence of ALK 
gene fusions. Depending on the central assessment of 
PD-L1 status (either > 1% or < 1%), patients were 
randomised in 1:1:1 ratio to a combination of nivolumab 
with ipilimumab, nivolumab alone, or standard chemo-
therapy (if PD-L1 expression was > 1%) or to a com-
bination of nivolumab with ipilimumab, a combination 
of nivolumab with chemotherapy, or standard chemo-
therapy (if PD-L1 expression was < 1%). The primary 
endpoint was overall survival in patients with PD-L1 ex-
pression > 1% compared between a combination of 
nivolumab and ipilimumab and standard chemotherapy 
(results of the second primary endpoint — a compari-
son of PFS in patients with tumour mutational burden 
[TMB] equal to or higher than 10 mutations per MB 
were published previously [3]). Patients assigned to the 
combination of nivolumab and ipilimumab received 
nivolumab at a dose of 3 mg/kg body weight every two 
weeks along with ipilimumab 1 mg/kg body weight every 
six weeks. Patients assigned to the nivolumab mono-
therapy received nivolumab at a fixed dose of 240 mg 
biweekly, and patients assigned to the combination of 
nivolumab with chemotherapy received nivolumab at 
a fixed-dose of 360 mg every three weeks along with stan-
dard platinum-based doublet chemotherapy every three 
weeks (up to four cycles of chemotherapy). The control 
arm for both PD-L1 > 1% and < 1% received standard 
treatment of platinum-based chemotherapy (patients 
with adenocarcinoma: up to four cycles of cisplatin or 
carboplatin with pemetrexed with an option of continu-
ing maintenance pemetrexed; patients with squamous 
carcinoma: up to four cycles of cisplatin or carboplatin 
with gemcitabine). The trial included 1189 patients with 
a confirmed PD-L1 expression of > 1% and 550 pa-
tients with PD-L1 expression of < 1%. After a median 
follow-up time of 29.3 months, the trial met its primary 
endpoint in patients with PD-L1 expression > 1%: 
median OS in patients receiving nivolumab and ipili-
mumab reached 17.1 months (95% CI 15.0–20.1) as 
compared to 14.9 months (95% CI 12.7–16.7) in patients 
receiving chemotherapy (p = 0.007). HR for death 
was 0.79 (97.2% CI 0.65–0.96) with a commentary 
that this should be interpreted along with analysis of 
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survival curves: initially favouring chemotherapy, then 
crossing and subsequentially favouring nivolumab and 
ipilimumab. Benefit from double immune blockade 
was confirmed in most subgroups, with the exception 
of patients with liver metastases and those without 
history of smoking. The response rate was 35.9% in 
patients receiving nivolumab and ipilimumab and 30% 
in patients receiving chemotherapy, with a median du-
ration of response of, respectively, 23.2 months (95% 
CI 15.2–32.2) and 6.2 months (95% CI 5.6–7.4). Benefit 
from a combination of nivolumab with ipilimumab was 
also observed in the population with PD-L1 expres-
sion < 1% (pre-planned descriptive analysis): median 
OS was 17.2 months (95% CI 12.7–22.0) in patients 
receiving immunotherapy combination as compared 
to 12.2 months (95% CI 9.2–14.3) in patients receiving 
chemotherapy, with an HR of 0.62 (95% CI 0.48–0.78). 
Similar results were seen in combined analysis of 
PD-L1 > 1% and PD-L1 < 1% populations: median OS 
was 17.2 months (95% CI 15.2–19.9) and 13.9 months 
(95% 12.2–15.1), respectively. Comparison of nivolumab 
and ipilimumab with nivolumab monotherapy showed 
numerically better results achieved with the combination 
in terms of two-year survival rate and median duration 
of response, both in PD-L1 > 1% and PD-L1 > 50% 
populations. Better results in terms of two-year sur-
vival rate and median duration of response were seen 
also with immunotherapy combination as compared to 
combination of nivolumab and chemotherapy in the 
population with PD-L1 expression < 1%. In a detailed 
analysis neither PD-L1 expression, TMB status, nor their 
combination allowed selection of patients who could 
derive greater benefit from a combination of nivolumab 
and ipilimumab. Despite the previously shown correla-
tion between TMB and median PFS [3], this has not 
translated into OS benefit. In terms of safety, the rate 
of grade 3 or greater adverse events was similar between 
the nivolumab-ipilimumab arm and the chemotherapy 
arm (32.8% and 36.0%, respectively). However, both 
severe adverse events (24.5% vs. 13.9%) and adverse 
events that led to treatment discontinuation (18.1% 
vs. 9.1%) were more common in patients receiving 
nivolumab with ipilimumab. No significant difference in 
rates of adverse events leading to death was seen (1.4% 
in the combination immunotherapy group versus 1.1% 
in the chemotherapy group). The published results did 
not include data regarding quality of life. 
The results of CheckMate 227 have a meaningful 
impact on the role of immunotherapy in the first-line 
treatment of patients with non-small cell lung cancer 
and justify skipping chemotherapy in the majority of 
patients. However, it seems that the benefit from com-
bined immunotherapy might be reduced in patients 
with PD-L1 expression 1–49%. The benefit seen in 
the whole population with PD-L1 expression > 1% is 
mostly driven by exceptional results obtained in patients 
with expression > 50%. Similar effects have also been 
reported in immunotherapy trials in different types of 
cancer. In practice, the patients with PD-L1 expression 
within 1–49% might be the best candidates for the com-
bination of immunotherapy and chemotherapy. Other 
factors limiting the benefit from combined immuno-
therapy are the presence of liver metastases and lack of 
smoking history, which may provide guidance regarding 
treatment individualisation. Additionally, CheckMate 
227 provided important, albeit negative, results assessing 
TMB as a predictive marker for immunotherapy. The 
idea that a higher number of genetic mutations increases 
the variety of presented neoantigens, promoting induc-
tion of immune response, does not translate into OS 
benefit. Unfortunately, none of the biomarkers reported 
in CheckMate 227 allow selection of a population with 
greater benefit from combined immunotherapy. Con-
sidering the remarkably high costs of such treatment, 
the lack of an adequate biomarker undermines wide 
implementation of combination immunotherapy into 
clinical practice. The growing potential of immunothera-
py in the first-line treatment of patients with non-small 
cell lung cancer is revolutionising both patient treatment 
and the functioning of health care systems. The greatest 
challenge in the upcoming years, especially in chronically 
underfinanced systems, will be optimisation of treatment 
to achieve the best results with an acceptable immuno-
therapy-associated financial burden.
The next PARP inhibitors proved to be effective in the treatment of patients with 
ovarian cancer
Treatment of patients with ovarian cancer is a sig-
nificant clinical challenge, despite its relative sensitivity 
to platinum-based chemotherapy, which can induce 
long-lasting responses. Unfortunately, the majority of 
patients achieving partial or complete response will 
eventually relapse with a reduced probability of re-in-
ducing response. One of the strategies evaluated in this 
setting is inhibition of PARP, the enzyme responsible 
for the repair of single-strain DNA breaks. Inhibition 
of PARP activity leads to the accumulation of sin-
gle-strain DNA breaks, which subsequently generates 
double-strain DNA breaks leading to cancer cell death. 
PARP inhibitors exhibit particular activity in the 
presence of other DNA repair dysfunctions, such as 
BRCA1/2 mutations or the presence of other mechanism 
of homologous repair deficiency (HDR). PARP inhibi-
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tion, initially developed as a salvage treatment, is useful 
also as a maintenance treatment after first-line therapy. 
Several different PARP inhibitors have proved effective 
as a salvage treatment (olaparib, rucaparib, veliparib), 
but until recently only olaparib has proved its role in 
the maintenance strategy. Now the situation is changing 
because the next two phase III trials evaluating PARP 
either as part of induction and maintenance treatment 
or just as maintenance treatment have been published.
The VELIA/GOG-3005 study, the results of which 
were published by Coleman et al. [4] on 28th Septem-
ber 2019 in the “New England Journal of Medicine”, 
evaluated veliparib used as an addition to standard 
first-line induction chemotherapy (carboplatin and 
paclitaxel) and continued as a maintenance treatment. 
This randomised, double-blinded, phase III trial includ-
ed chemotherapy-naive patients with stage III or IV 
(according to International Federation of Gynaecology 
and Obstetrics; FIGO) high-grade serous carcinoma of 
the ovary, fallopian tube, or peritoneum, irrespective of 
BRCA1/2 and HDR status. Veliparib was used orally at 
a dose of 150 mg twice daily during chemotherapy and 
then 300 mg twice daily with a possible escalation to 
400 mg twice daily as a maintenance treatment. Patients 
were randomised in a 1:1:1 ratio to either veliparib used 
during both induction and maintenance phases, veliparib 
used during induction phase and placebo during mainte-
nance phase, or to placebo used both during induction 
and maintenance phases (control arm). The primary 
endpoint was the comparison of PFS between patients 
receiving veliparib in the induction and maintenance 
phase with the control arm, evaluated hierarchically first 
in patients with BRCA mutations, then in patients with 
confirmed HDR, and finally in the intention-to-treat 
(ITT) population. One of the key secondary endpoints 
was overall survival. Altogether, 1140 patients were re-
cruited into the trial, among whom 298 (26%) had BRCA 
mutations (19% germinal mutations and 7% somatic 
tumour mutations) and 627 (55%) had confirmed HDR 
status. After a median follow-up of 28 months, the trial 
met its primary endpoint in all hierarchically analysed 
groups. In patients with BRCA mutations the median 
PFS reached 34.7 months in the veliparib arm compared 
to 22.0 months in the placebo arm (HR for progression 
or death 0.44; 95% 0.28–0.68; p < 0.001). In HDR 
patients the PFS reached, respectively, 31.9 months as 
compared to 20.5 months (HR 0.57; 95% CI 0.43–0.76; 
p < 0.001), and in ITT analysis 23.5 vs. 17.3 months (HR 
0.68; 95% CI 0.56–0.83; p < 0.001). The achieved effect 
was seen in most of the analysed subgroups with the 
exception of patients with macroscopically non-radical 
cytoreduction — no benefit from veliparib was seen 
in this group. Patients without confirmed HDR also 
gained less benefit from veliparib when compared to 
patients with either HDR or BRCA mutations. Due 
to data immaturity, OS analysis was impossible. In the 
safety analysis a modest increase of adverse events was 
seen in patients receiving veliparib in the induction and 
maintenance phases (88% vs. 77% in the placebo arm), 
although this did not reduce the chemotherapy intensity. 
The most common veliparib-related adverse event was 
thrombocytopaenia. Among patients receiving veliparib 
one case of myelodysplastic syndrome and one case of 
acute myeloid leukaemia were seen, which is comparable 
to the risk described with other PARP inhibitors. Qual-
ity-of-life comparison showed no difference between 
study arms.
Results of the second trial were published by 
González-Martín et al. [5] also on 28th September 
2019 in the “New England Journal of Medicine”. The 
PRIMA/ENGOT-OV26/GOG-3012 trial was a ran-
domised, double-blinded, phase III trial that compared 
niraparib, a novel PARP inhibitor, with placebo in 
patients with FIGO stadium III–IV ovarian, fallopian 
tube, or peritoneal cancers, who achieved response 
(CR or PR) after induction chemotherapy. Patients 
were randomised in a 2:1 ratio to either neratinib 
(administered at a dose of 300 mg once daily, although 
on-trial amendment allowed reduction of initial dose 
to 200 mg per day in patients under 77 kg body weight 
or with thrombocytopaenia below 150,000 platelets 
per cubic millimetre) within 12 weeks after finishing 
induction chemotherapy. The primary endpoint was PFS 
assessed hierarchically in the population with positive 
HDR status and then in the overall population. Key 
secondary endpoints included overall survival. The trial 
included 733 patients, and after a median follow-up 
time of 13.8 months it met its primary endpoint. In 
patients positive for HDR the median PFS reached 
21.9 months in the niraparib group and 10.4 months in 
the placebo group (HR for progression or death 0.43; 
95% CI 0.31–0.59; p < 0.001). In the overall population 
the difference was 13.8 months in the intervention arm 
as compared to 9.2 months in the control arm (HR 
0.62; 95% CI 0.50–0.76; p < 0.001). This effect was 
maintained in all analysed subgroups. At the point of 
analysis OS data were immature (about 11% of events), 
but per-protocol OS analysis was undertaken. The rate 
of two-year survival was 84% in the niraparib arm and 
77% in the placebo arm (HR 0.61; 95% CI 0.27–1.39; 
not statistically significant). The most common adverse 
events associated with niraparib were anaemia, throm-
bocytopaenia, and neutropaenia. The rate of grade 3 or 
worse adverse events was 70.5% in patients receiving 
niraparib and 18.9% in patients receiving placebo. Dose 
reductions were required in 70.9% of patients receiv-
ing niraparib and 8.2% of patients receiving placebo, 
with a discontinuation rate due to adverse events of, 
respectively, 12% and 2.5%. Quality-of-life comparison 
showed no difference between study arms.
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The two presented trials broaden the availability of 
PARP inhibitors for patients with ovarian cancer, con-
firming the potential of PARP inhibition also at the early 
phase of treatment. The differences between specific 
compounds and in trial designs limits direct comparison, 
but also enables individualisation of treatment according 
to risk-factor profile, patient performance, and prefer-
ences. From this perspective, diversity is highly desirable.
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